Fas C-Terminal Tripeptide Mechanisms, Clinical Value, and Re

Fas C-Terminal Tripeptide: Mechanisms, Clinical Value, and Research Perspectives in Apoptosis Modulation

Introduction
Fas C-Terminal Tripeptide is a synthetic peptide fragment derived from the C-terminal region of the Fas receptor (also known as CD95 or APO-1), a critical member of the tumor necrosis factor (TNF) receptor superfamily. The Fas receptor plays a pivotal role in the regulation of programmed cell death (apoptosis), a process essential for tissue homeostasis, immune regulation, and the elimination of damaged or malignant cells (Nagata, 1997, Cell). The Fas C-Terminal Tripeptide specifically mimics the terminal three amino acids of the Fas cytoplasmic domain, enabling it to modulate Fas-mediated apoptotic signaling pathways.

Mechanistically, the Fas C-Terminal Tripeptide acts as a competitive inhibitor of the interaction between the Fas receptor and its downstream adaptor protein, Fas-associated death domain (FADD). By interfering with this interaction, the peptide can attenuate the formation of the death-inducing signaling complex (DISC), thereby modulating the initiation of the caspase cascade and subsequent apoptotic events (Chinnaiyan et al., 1995, Science). This unique mechanism positions the Fas C-Terminal Tripeptide as a valuable research tool for dissecting apoptosis pathways and as a potential therapeutic modulator in diseases characterized by aberrant cell death.

[Related: β nicotinamide mononucleotide] Clinical Value and Applications
The clinical value of the Fas C-Terminal Tripeptide lies in its ability to selectively modulate Fas-mediated apoptosis, a process implicated in a wide range of pathological conditions. Excessive or inappropriate activation of Fas signaling contributes to the pathogenesis of autoimmune diseases (e.g., systemic lupus erythematosus), neurodegenerative disorders (e.g., amyotrophic lateral sclerosis), and ischemia-reperfusion injuries (Peter & Krammer, 2003, Cell Death Differ). Conversely, insufficient Fas signaling can facilitate tumor immune evasion and resistance to apoptosis in cancer cells (Owen-Schaub et al., 1994, Proc Natl Acad Sci USA).

In preclinical models, the Fas C-Terminal Tripeptide has demonstrated utility in protecting normal tissues from apoptosis-induced damage, such as in hepatic and neuronal injury models (Zhang et al., 2000, J Biol Chem). Furthermore, its application in cancer research enables the elucidation of resistance mechanisms to Fas-mediated cell death, informing the development of combination therapies that sensitize tumor cells to immune-mediated clearance.

[Related: 765 lps] Key Challenges and Pain Points Addressed
Current therapeutic strategies targeting apoptosis often lack specificity, resulting in off-target effects and unintended cytotoxicity. Small molecule inhibitors of caspases or pan-TNF inhibitors, for example, can disrupt multiple signaling pathways, leading to immunosuppression or impaired tissue repair (Ashkenazi & Dixit, 1998, Science). The Fas C-Terminal Tripeptide addresses these challenges by offering a targeted approach to modulate a specific protein-protein interaction within the Fas pathway.

Additionally, resistance to apoptosis is a hallmark of many cancers, often mediated by mutations or downregulation of Fas or its downstream effectors. By providing a tool to dissect the molecular determinants of Fas signaling, the Fas C-Terminal Tripeptide facilitates the identification of novel therapeutic targets and the rational design of sensitizing agents (Fulda & Debatin, 2006, Nat Rev Drug Discov).

[Related: olaparib structure] In autoimmune and inflammatory diseases, excessive Fas activation leads to tissue destruction and chronic inflammation. The Fas C-Terminal Tripeptide offers a means to transiently inhibit Fas signaling, potentially reducing tissue damage without broadly suppressing immune function.

Literature Review
1. **Chinnaiyan et al. (1995, Science)**: This seminal study elucidated the molecular interaction between the Fas receptor and FADD, demonstrating that the death domain of Fas is essential for DISC formation and caspase activation. Synthetic peptides corresponding to the Fas C-terminal region were shown to competitively inhibit this interaction, providing a mechanistic basis for the use of Fas C-Terminal Tripeptide as an apoptosis modulator.

2. **Zhang et al. (2000, J Biol Chem)**: In a hepatic injury model, administration of a Fas C-terminal peptide significantly reduced hepatocyte apoptosis and improved survival. The study highlighted the peptide’s potential in protecting against Fas-mediated tissue injury.

3. **Peter & Krammer (2003, Cell Death Differ)**: This review summarized the role of Fas signaling in immune regulation and autoimmunity, emphasizing the therapeutic potential of modulating Fas-FADD interactions in diseases characterized by excessive apoptosis.

4. **Owen-Schaub et al. (1994, Proc Natl Acad Sci USA)**: The authors demonstrated that loss of Fas expression in tumor cells contributes to immune evasion. The study underscored the importance of Fas pathway modulation in cancer therapy and the need for tools such as the Fas C-Terminal Tripeptide to investigate resistance mechanisms.

5. **Fulda & Debatin (2006, Nat Rev Drug Discov)**: This review discussed the challenges of overcoming apoptosis resistance in cancer, highlighting the value of targeted modulators of death receptor pathways, including peptide-based inhibitors.

6. **Ashkenazi & Dixit (1998, Science)**: The authors reviewed the therapeutic landscape of apoptosis modulation, noting the limitations of non-specific inhibitors and the promise of targeted approaches such as peptide mimetics.

7. **Nagata (1997, Cell)**: This comprehensive review detailed the molecular biology of Fas signaling, providing foundational knowledge for the development of peptide-based modulators.

Experimental Data and Results
Experimental studies utilizing the Fas C-Terminal Tripeptide have provided compelling evidence for its efficacy in modulating apoptosis. In vitro assays demonstrate that the peptide inhibits Fas-induced caspase-8 activation and subsequent DNA fragmentation in Jurkat T cells, with a dose-dependent reduction in apoptotic markers (Chinnaiyan et al., 1995, Science).

In vivo, Zhang et al. (2000, J Biol Chem) administered the Fas C-terminal peptide to mice subjected to Fas ligand-induced hepatic injury. Treated animals exhibited a significant decrease in TUNEL-positive hepatocytes and lower serum transaminase levels compared to controls, indicating reduced liver damage. Survival analysis revealed a marked improvement in the peptide-treated group, supporting its protective role against Fas-mediated apoptosis.

Additional studies in neuronal cell models have shown that the Fas C-Terminal Tripeptide can prevent apoptosis induced by neurotoxic insults, suggesting potential applications in neurodegenerative disease research (Peter & Krammer, 2003, Cell Death Differ). Importantly, these effects are specific to Fas-mediated pathways, as the peptide does not inhibit apoptosis triggered by other death receptors or intrinsic mitochondrial signals.

Usage Guidelines and Best Practices
The Fas C-Terminal Tripeptide is typically supplied as a lyophilized powder, with recommended reconstitution in sterile water or appropriate buffer to achieve a working concentration. For in vitro applications, concentrations ranging from 10 to 100 μM are commonly employed, depending on cell type and experimental design (Chinnaiyan et al., 1995, Science). It is advisable to perform preliminary dose-response studies to determine the optimal concentration for specific cell lines or tissues.

For in vivo studies, dosing regimens should be guided by published protocols and pilot experiments, taking into account the route of administration (e.g., intravenous, intraperitoneal) and the pharmacokinetic properties of the peptide. Co-administration with protease inhibitors may enhance peptide stability in biological fluids.

Best practices include the use of appropriate controls, such as scrambled peptide sequences or vehicle-only treatments, to confirm the specificity of observed effects. Researchers should also monitor for potential off-target effects and assess cell viability, apoptosis markers, and downstream signaling events.

Storage conditions typically involve keeping the lyophilized peptide at -20°C, with aliquots prepared to minimize freeze-thaw cycles. Reconstituted solutions should be used promptly or stored at 4°C for short-term use.

Future Research Directions
While the Fas C-Terminal Tripeptide has established utility as a research tool, several avenues remain for further investigation. Key areas for future research include:

1. **Optimization of Peptide Stability and Delivery**: Enhancing the in vivo half-life and tissue penetration of the peptide through chemical modifications (e.g., PEGylation, cyclization) or nanoparticle-based delivery systems.

2. **Therapeutic Applications in Disease Models**: Expanding preclinical studies to assess the efficacy of the peptide in models of autoimmune disease, neurodegeneration, and organ transplantation, with a focus on safety and long-term outcomes.

3. **Combination Therapies**: Investigating the synergistic effects of Fas C-Terminal Tripeptide with other apoptosis modulators, immune checkpoint inhibitors, or chemotherapeutic agents in cancer models.

4. **Biomarker Development**: Identifying predictive biomarkers of response to Fas pathway modulation, enabling patient stratification and personalized therapeutic approaches.< Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 48 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541688